Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Weiyu Ge

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0293-7804; OpenAlex author ID A5081605442. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2021: 1 paper · 2022: 8 papers · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper

Papers 14

  1. A novel defined cuproptosis-related signature score to predict prognosis and immunotherapy efficacy in pancreatic cancer. Co-author DOI 10.3892/ol.2025.15337↗
  2. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Co-author DOI 10.1186/s12943-024-01965-5↗
  3. PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. Co-author DOI 10.1016/j.canlet.2023.216095↗
  4. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216206↗
  5. Cuproptosis-related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients. First author DOI 10.1049/syb2.12068↗
  6. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.103897↗
  7. Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. Co-author DOI 10.1155/2022/5634887↗
  8. HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. Co-author DOI 10.1186/s12935-022-02807-4↗
  9. Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer. Co-author DOI 10.18632/aging.204031↗
  10. Cuproptosis-related lncRNAs are correlated with metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients First author DOI 10.21203/rs.3.rs-1645540/v1↗
  11. A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. Co-author DOI 10.3389/fcell.2022.1001606↗
  12. Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. First author DOI 10.3389/fcell.2022.942225↗
  13. A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. Co-author DOI 10.3390/ijms24010156↗
  14. SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer. Co-author DOI 10.1038/s41388-021-01864-9↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaofei Zhang · 12 shared papers, 2022–2024 · strength 1.74
  2. Jiujie Cui · 11 shared papers, 2022–2024 · strength 1.61
  3. Tiebo Mao · 11 shared papers, 2022–2024 · strength 1.57
  4. Shengbai Xue · 9 shared papers, 2022–2023 · strength 1.32
  5. Liwei Wang · 6 shared papers, 2022–2023 · strength 0.82
  6. Yanling Wang · 4 shared papers, 2022–2025 · strength 0.74
  7. Jiayu Yao · 5 shared papers, 2022 · strength 0.64
  8. Shumin Li · 3 shared papers, 2022–2023 · strength 0.44
  9. Liwei Wang · 3 shared papers, 2022 · strength 0.44
  10. Ming Quan · 2 shared papers, 2023–2024 · strength 0.34
  11. Liwei Wang · 2 shared papers, 2022–2023 · strength 0.30
  12. Yanling Wang · 2 shared papers, 2022–2023 · strength 0.29
  13. Lei Wang · 1 shared paper, 2024 · strength 0.18
  14. Haiyan Yang · 1 shared paper, 2024 · strength 0.18
  15. Yanling Wang · 1 shared paper, 2022 · strength 0.17
  16. Xiao Zhang · 1 shared paper, 2022 · strength 0.15
  17. Junjian Li · 1 shared paper, 2021 · strength 0.11
  18. Yue Yu · 1 shared paper, 2021 · strength 0.11
  19. Hongxia Wang · 1 shared paper, 2021 · strength 0.11
  20. Feng Jiao · 1 shared paper, 2022 · strength 0.11
  21. Yingbin Liu · 1 shared paper, 2022 · strength 0.11
  22. Jiong Hu · 1 shared paper, 2022 · strength 0.11
  23. Yongwei Sun · 1 shared paper, 2022 · strength 0.11
  24. Yu Wang · 1 shared paper, 2022 · strength 0.11
  25. Yuexiang Wang · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.